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Abstract
Background: Alzheimer’s disease (AD) is characterized by senile plaques, extracellular deposits composed primarily
of amyloid–beta (Aβ), and neurofibrillary tangles, which are abnormal intracellular inclusions containing
hyperphosphorylated tau.
The amyloid cascade hypothesis posits that the deposition of Aβ in the brain parenchyma initiates a sequence of
events that leads to dementia. However, the molecular process by which the extracellular accumulation of Aβ
peptides promotes intracellular pathologic changes in tau filaments remains unclear. To elucidate this process, we
presumed that astrocytes might trigger neuronal reactions, leading to tau phosphorylation. In this study, we
examined AD pathology from the perspective of the astrocyte-neuron interaction.
Results: A cytokine-array analysis revealed that Aβ stimulates astrocytes to release several chemical mediators that are
primarily related to inflammation and cell adhesion. Among those mediators, insulin-like growth factor (IGF)-binding
protein 3 (IGFBP-3) was highly upregulated.
In AD brains, the expression of IGFBP-3 was found to be increased by western blot analysis, and increased expression
of IGFBP-3 was observed in astrocytes via fluorescence microscopy.
In addition, we reproduced the increase in IGFBP-3 after treatment with Aβ using human astrocytoma cell lines and
found that IGFBP-3 was expressed via calcineurin. In AD brains, the activated forms of calcineurin were found to be
increased by western blot analysis, and increased expression of calcineurin was observed in astrocytes via fluorescence
microscopy.
When Ser9 of glycogen synthase kinase-3β (GSK-3β) is phosphorylated, GSK-3β is controlled and tau phosphorylation is
suppressed. Aβ suppresses the phosphorylation of GSK-3β, leading to tau phosphorylation. In this study, we found that
IGF-Ι suppressed tau phosphorylation induced by Aβ, although IGFBP-3 inhibited this property of IGF-Ι. As a result,
IGFBP-3 contributed to tau phosphorylation and cell death induced by Aβ.
Conclusions: Our study suggested that calcineurin in astrocytes was activated by Aβ, leading to IGFBP-3 release. We
further demonstrated that IGFBP-3 produced by astrocytes induced tau phosphorylation in neurons. Our study
provides novel insights into the role of astrocytes in the induction of tau phosphorylation and suggests that IGFBP-3
could be an important link between Aβ and tau pathology and an important therapeutic target.
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Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disease and the most prevalent type of dementia in
the elderly population. AD is clinically characterized by
cognitive decline and pathologically characterized by se-
nile plaques, neurofibrillary tangles (NFT) and glial cell
activation [1–7].
Senile plaques are extracellular deposits that are com-
posed primarily of amyloid–beta (Aβ) [3], which is pro-
teolytically cleaved from amyloid precursor protein
(APP) [8, 9]. Aβ is widely considered to be the primary
pathological agent in AD [3, 5, 10] because mutations of
the genes that encode APP and presenilin, which are en-
zymes related to the cleavage of Aβ, are known to cause
early-onset familial AD [11, 12]. In addition, transgenic
mice that overexpress mutated forms of human APP are
widely used as AD models.
NFT are abnormal intracellular inclusions that con-
tain hyperphosphorylated tau, which is a microtubule-
associated protein [13, 14]. Aβ oligomers are known to
be associated with tau hyperphosphorylation [4], which
leads to the disruption of the neuronal cytoskeleton,
followed by neurodegeneration and cell death [15, 16].
The amyloid cascade hypothesis posits that the depos-
ition of the Aβ peptide in the brain parenchyma initiates
a sequence of events that ultimately leads to dementia
[17]. However, the molecular process by which the extra-
cellular accumulation of Aβ peptides promotes intracellu-
lar pathologic changes in tau filaments remains unknown,
although many researchers attempted to elucidate this
process. To date, various hypotheses have been proposed
to elucidate this mechanism. For instance, Gamblin et al.
reported that Aβ peptides promoted pathological tau fila-
ment assembly in neurons by triggering caspase-mediated
cleavage of tau and generating a proteolytic product with
enhanced polymerization kinetics [18]. On the other hand,
the astrocyte-neuron interaction has also attracted atten-
tion. Astrocytes were reported to be necessary for and to
accelerate Aβ-induced tau phosphorylation [19]. Talantova
et al. revealed that Aβ engaged α7 nicotinic acetylcholine
receptors to induce the release of astrocytic glutamate,
which then activated extrasynaptic NMDA receptors on
neurons. The activity of these NMDA receptors might
reflect early synaptic injury [20]. These studies led us to
consider the possibility that environmental factors sur-
rounding neurons might be important for tau phosphoryl-
ation. Thus, we presumed that glial cells might trigger
neuronal reactions, leading to tau phosphorylation.
Astrocyte activation is inevitably seen in the AD brain
[21–26]. Reactive astrocytes are found around amyloid
plaques in AD brains, as well as in animal models [27, 28],
suggesting that Aβ drives astrocytes to become activated.
Aβ can alter glial homeostasis, including the dysregulation
of Ca2+ signaling [29–31]. One of the key players in Ca2+
signaling is calcineurin (CaN), which is a calcium-related
phosphatase downstream of Ca2+ [32, 33]. In the litera-
ture, CaN was suggested to be involved in AD. Many
activated astrocytes in the AD brain and in the mouse AD
model express high levels of CaN [34–36]. CaN is
known to be elevated during the pathological process
of AD [36–39], but several mechanisms have been
suggested to underlie this observation. Some reports
indicate that Aβ itself may activate CaN signaling in
astrocytes [36, 40–43]. In turn, CaN may strongly
activate transcription factors involved in cytokine pro-
duction and phenotype switching, according to other
reports [44, 45].
Because astrocytes and microglia are known to produce
several proinflammatory signaling molecules [46–48], we
used differential antibody analysis to compare the expres-
sion levels of these proteins between Aβ42-treated and
control peptide-treated astrocytes. One of the highly up-
regulated proteins in Aβ42-treated astrocytes was insulin-
like growth factor (IGF)-binding protein 3 (IGFBP-3),
which is known to be involved in IGF signaling. We pre-
sume that IGFBP-3, which is released from astrocytes after
Aβ42 stimulation, may be a key molecule in the associ-
ation between astrocytes and neurons in AD. In this study,
we demonstrated the following:
1) Activated astrocyte releases IGFBP-3 in response to
Aβ via the CaN cascade.
2) IGFBP-3 is localized within astrocytes in the
proximity of Aβ plaques and within Aβ plaques
themselves in the AD brain.
3) IGFBP-3 induces tau phosphorylation in neurons,
which leads to neuronal death.
Thus, we conclude that IGFBP-3 is a key molecule
that can link Aβ with NFT and may be a desirable thera-
peutic target.
Results
Aβ stimulates murine astrocytes to release several
chemical mediators
Aβ has been proposed to stimulate astrocytes to release
several chemical mediators. To identify the chemical me-
diators released by murine astrocytes after Aβ treatment, we
performed a cytokine-array analysis. The culture medium
from murine primary astrocytes was collected after a 48-h
treatment with 1 μM Aβ1–42 or synthetic peptide Aβ42-1
(inverted sequence of Aβ) and subjected to analysis.
Representative data obtained from three independent
experiments are shown in Fig. 1b. Quantification data of
three experiments are Fig. 1c. Array analyses indicated
that the mediators released from astrocytes in response
to Aβ1–42 were primarily related to inflammation and
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cell adhesion (Fig. 1a). Among these proteins, IGFBP-3
was highly upregulated and selected for further
investigation.
The expression of IGFBP-3 is increased in AD brains, as
indicated by western blotting analysis
IGF-binding proteins (IGFBPs) have a strong affinity
for IGFs and are known to regulate the bioactivity of
IGFs. Serum IGFBP-3, which is one of six IGFBPs, was
previously reported to be upregulated in AD patients
[49]. To test whether the levels of IGFBP-3 were in-
creased in the AD brain, we analyzed the protein levels
of IGFBP-3 in the temporal cortices of human AD pa-
tients and age-matched non-AD controls. As expected,
western blot analysis revealed increased expression
levels of IGFBP-3 in AD brains in comparison to non-
AD controls (Fig. 2a). A quantitative analysis demon-
strated that the ratio of IGFBP-3 to β-actin was signifi-
cantly increased in AD brains in comparison to non-AD
controls (n = 5, 188.1 ± 23.9 %, p < 0.05; Fig. 2b).
Upregulated IGFBP-3 co-localizes with astrocytes in AD
patients, as indicated by fluorescence microscopy
Next, we asked whether IGFBP-3 expression was actually
upregulated in astrocytes from AD brains using fluores-
cence microscopy. Triple-labeling experiments (IGFBP-3,
GFAP, and Aβ) revealed that fewer astrocytes were immu-
nolabeled with anti-IGFBP-3 in control brains (Fig. 3). In
contrast, increased expression of IGFBP-3 was observed in
astrocytes from AD patients, especially in gemistocytic
astrocytes in the proximity of Aβ plaques. Moreover,
IGFBP-3 was frequently observed within Aβ plaques (Fig. 3).
These results indicate that IGFBP-3 is upregulated in astro-
cytes from AD brains.
Aβ stimulates human astrocytoma cell lines to upregulate
IGFBP-3 at both the mRNA and protein levels
To determine whether Aβ treatment upregulates the tran-
scription of IGFBP-3, we treated human astrocytoma cells
(H4 cells) with 1 μM Aβ1–42 for 24 h. After treatment,
mRNA was obtained from the cells, and the samples were
A
B C
Fig. 1 Protein list upregulated by Aβ1-42 and their quantification results from a cytokine-array analysis (a). The list of reproducibly upregulated proteins
was obtained from three independent cytokine-array analyses. Proteins related to inflammation and cell adhesion were shown to be upregulated. Real
data and quantitative analyses are shown (b, c). The culture medium from primary murine astrocytes was collected after a 48-h treatment with 1 μM
Aβ1–42 or synthetic peptide Aβ42-1 (inverted sequence of Aβ) and was subjected to analysis. The left spots are the results obtained for Aβ1–42, and the
right spots are the results obtained for the control (b). On the membrane of the cytokine-array analysis, Anti-HRP and anti-streptavidin are laid out as
positive control signals, which can be used to identify the orientation and help normalize the results from the different arrays being compared. As a re-
sult of densitometry for these normalized spots, proteins that had significantly increased were selected
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subsequently subjected to quantitative RT-PCR analysis.
Fig. 4a shows that the levels of IGFBP-3 mRNA were
significantly increased after treatment with Aβ1–42, as com-
pared with a control peptide (n = 6, 170.2 ± 8.7 %, p < 0.001
in comparison to the control). To verify IGFBP-3 upregula-
tion at the protein level, we treated H4 cells with 1 μM
Aβ1–42 for 48 h and subjected the cell lysate and the
medium to western blot and ELISA analyses, respectively.
We observed increased levels of IGFBP-3 in the Aβ1–42-
treated cell preparations in comparison to control peptide-
treated preparations using western blot (n = 4, 552.5
± 14.1 %, p < 0.001) and ELISA (n = 7, 255.4 ± 26.0 %,
p < 0.001) (Fig. 4b, c and d).
FK506 treatment of human astrocytoma cells attenuates
the effect of Aβ on IGFBP-3 at both the mRNA and the
protein levels
Previous reports showed that CaN levels increased dur-
ing the time course of AD [36–39]. CaN is also known
to be highly expressed in many activated astrocytes in
the AD brain and in the mouse model of AD [34–36].
Thus, we focused on the CaN cascade as one of the
pathways through which astrocytes release IGFBP-3 in
response to Aβ treatment. We examined whether the
CaN inhibitor FK506 could affect the release of IGFBP-3
from astrocytes. We treated H4 cells with 1 μM Aβ1–42
and 1 μM FK506 for 24 h. Real-time PCR revealed that
the levels of IGFBP-3 mRNA were significantly reduced
after treatment with FK506, in comparison to cells that
were not treated with FK506 (n = 6, p < 0.001; Fig. 4a).
To examine the effect of FK506 on intracellular and
extracellular expression of the IGFBP-3 protein, we
treated H4 cells with 1 μM Aβ1–42 and FK506 for 48 h.
The levels of intra- and extra-cellular IGFBP-3 were found
to be reduced in FK506-treated cells in comparison to un-
treated cells, as indicated by western blot (n = 4, p < 0.001)
and ELISA (n = 7, p < 0.001), respectively (Fig. 4b, c and
d). These data suggested that astrocytes expressed IGFBP-
3 via the CaN cascade.
Activated forms of CaN are increased in AD brains
To confirm that the CaN cascade is actually activated in
the AD brain, we analyzed the levels of activated CaN in
temporal cortices from human AD patients in comparison
to samples from age-matched non-AD controls. CaN is
composed of a 60-kDa catalytic subunit (PPP3CA) and a
19 kDa calcium-binding regulatory subunit (PPP3R1) [50].
The 60-kDa catalytic subunit possesses a catalytic domain,
a regulatory subunit binding domain, a calmodulin bind-
ing domain, and an autoinhibitory domain at the C-
terminus [51]. When Ca2+ and calmodulin bind to CaN,
the autoinhibitory domain is detached and CaN becomes
Fig. 2 IGFBP-3 expression in human brains. Brain homogenates of temporal cortexes from AD patients (AD, n = 5) and age-matched non-AD
controls (control, n = 5) were analyzed via western blot using anti-IGFBP3 and β-actin antibodies (a). The band densities were quantified using
Image J. The IGFBP3/β-actin ratio was calculated and analyzed using Mann-Whitney’s U test. The IGFBP3/β-actin ratio was significantly increased
in the brains of AD patients (b, 188.1 ± 23.9 %, p < 0.05). The data represent the mean ± SE. * indicates statistically significant differences (*p < 0.05)
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activated. Activated CaN is identified as a 45 kDa protein
by western blot. Fig. 5a shows that the activated forms of
CaN were increased in AD brains in comparison to non-
AD controls (n = 5, 164.1 ± 11.4 %, p < 0.05; Fig. 5b).
Upregulated CaN co-localizes with astrocytes in AD
patients, as indicated by fluorescence microscopy
Next, we examined whether CaN expression was actually
upregulated in astrocytes from AD brains using fluores-
cence microscopy. As expected, increased expression of
CaN was localized to astrocytes from AD patients, espe-
cially in proximity to Aβ plaques, although a small amount
of CaN co-localized with astrocytes from control brains
(Fig. 6a-6). We counted the number of GFAP-positive cells
that expressed CaN and compared this value between
AD and control samples. More astrocytes expressed
CaN in AD brains than in control brains (n = 5, 210.3 ±
2.2 %, p < 0.05; Fig. 6k).
IGF-Ι suppresses glycogen synthase kinase-3β and tau
phosphorylation, although IGFBP-3 counteracts the effect
of IGF-Ι
IGF signaling is known to be closely linked to glycogen
synthase kinase-3β (GSK-3β) signaling. IGF-I stimulation
was reported to induce prolonged phosphorylation of
GSK-3β (at Ser9) via the PI3K pathway [52]. GSK-3β is a
well-known phosphorylase of the tau protein. Previous
reports have shown that IGF-Ι inhibits GSK-3β in neural
cells, resulting in tau hyperphosphorylation [53, 54].
Given that IGFBP-3 acts as an inhibitor of IGF signaling,
we focused on GSK-3β signaling to examine the effect of
IGFBP-3 on tau phosphorylation in primary neurons.
GSK-3β activity is known to be controlled by inhibi-
tory phosphorylation at the Ser9 residue. We examined
the effect of IGF-Ι and/or IGFBP-3 on inhibitory phos-
phorylation of GSK-3β. Interestingly, Aβ reduced Ser9
phosphorylation of GSK-3β (n = 6, p < 0.01), but IGF-Ι
restored the levels of Ser9 phosphorylation (p < 0.001;





Fig. 3 IGFBP-3 in astrocytes from human brains. Confocal images from a triple-fluorescence immunohistochemical study of β-amyloid stained with
FSB (blue) (a and e), astrocytes stained with GFAP (green) (b, f, i and l) and IGFBP3 (red) (c, g, j and m) are shown. D, H, K and N are merged images.
Representative images from a control brain (a-d) and an AD brain (e-h) are shown. Higher magnification images from another control (i-k) and from
AD patients (l-n) are shown. Little IGFBP-3 was detectable in astrocytes from control brains (c, d, j and k, white arrowheads), whereas increased
expression of IGFBP-3 was observed in astrocytes from AD patients (g and h, white arrows), especially in gemistocytic astrocytes (m and n) in the
proximity of Aβ plaques. Moreover, IGFBP-3 frequently co-existed with β-amyloid within Aβ plaques (g and h, white circle). These human brain samples
were from the temporal cortex
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Fig. 7a and b,). IGFBP-3 precluded the IGF-induced Ser9
phosphorylation (p < 0.01).
Because the hyperphosphorylation of tau is characteristic
of AD pathology, we examined tau phosphorylation. As re-
ported previously, Aβ induced tau phosphorylation in pri-
mary murine neurons after 48 h of treatment, as detected
by the AT8 antibody (Fig. 7c). We further investigated the
effect of IGF-Ι and/or IGFBP-3 on Aβ-induced phosphor-
ylation of tau. Although IGF-Ι tended to suppress tau
phosphorylation, IGFBP-3 counteracted the effect of IGF-Ι
(p < 0.05; Fig. 7c and d). We did the same experiment by
using another antibody, AT180, which identified different
phosphorylation site of tau from AT8. The results are
shown in supplementary figure (Additional file 1). This re-
sult was compatible with the one from AT8. Because both
phosphorylation sites are controlled by GSK-3β, this result
supports that IGF-Ι and IGFBP-3 affect GSK-3β, which
leads to tau phosphorylation.
Astrocyte-cultured media induce tau phosphorylation in
primary murine neurons
In AD brain, IGFBP-3 released from astrocytes is sup-
posed to actually induce phosphorylation of tau in neu-
rons. To reproduce this reaction, we did an additional
experiment in vitro. We examined phosphorylation of tau
in murine primary neuron when treated by astrocyte-
cultured media. Given regarded non cell-cultured media
as control, we found astrocyte-cultured media induced tau
phosphorylation in primary murine neurons in compari-
son to the control.as detected by both the AT8 antibody




Fig. 4 mRNA of intra- and extracellular IGFBP-3 are increased by Aβ via calcineurin in cultured cells. Human astrocytoma cells (H4 cells) were treated
with 1 μM Aβ1–42 or control peptide for 24 h. mRNA was extracted and subjected to quantitative RT-PCR. The levels of IGFBP-3 mRNA were significantly
increased after treatment with Aβ1–42, compared with the control peptide (a, n = 6, 170.2 ± 8.7 %, p < 0.001). Simultaneous treatment with both 1 μM
Aβ1–42 and 1 μM FK506 for 24 h downregulated the levels of IGFBP-3 mRNA, compared with Aβ1–42 treatment alone (a, n = 6, p < 0.001). The data
represent the mean ± SE. * indicates statistically significant differences (***p < 0.001). b-d Western blotting and ELISA were performed to verify the
upregulation of both intra- and extracellular IGFBP-3 protein levels after 48 h of treatment with 1 μM Aβ1–42 or control peptide. Increased levels of
IGFBP-3 were observed in the Aβ1–42-treated cell preparations in comparison to preparations treated with the control peptide treatment, as indicated
by western blot (c, n = 4, 552.5 ± 14.1 %, p < 0.001) and ELISA (d, n = 7, 255.4 ± 26.0 %, p < 0.001). FK506 treatment significantly reduced the levels of
intra- and extracellular IGFBP-3, as demonstrated by western blot (c, n = 4, p < 0.001) and ELISA (d, n = 7, p < 0.001), respectively. The data represent the
mean ± SE. * indicates statistically significant differences (***p < 0.001)
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Figure 7F are the ratio to the control of AT8 (n = 3
157.34 ± 3.44 %, p < 0.001) and AT180 (n = 3 133.63 ±
1.96 %, p < 0.05), respectively, which value was corrected
by total tau and βactin. This result is compatible with
the one for IGFBP-3 (Fig. 7c and d).
IGFBP-3 inhibits the pro-survival effect of IGF-Ι
Next, we performed an MTT assay to examine the in-
fluence of IGFBP-3 on cell death. IGF-Ι rescued
primary murine neurons from Aβ–induced cell death
(n = 16, p < 0.05). On the other hand, IGFBP-3 inhib-
ited the pro-survival effect of IGF-Ι (p < 0.05; Fig. 7g).
This result was compatible with the tau phosphoryl-
ation results.
Discussion
An accumulating number of reports suggest that Aβ is
involved in AD pathogenesis. Aβ, observed in the brain
parenchyma, is generally believed to initiate a sequence
of events that leads to dementia and a sequence of
pathological changes including NFT. However, the
molecular process that directly connects Aβ and NFT
has not yet been revealed. We thought that the key
player must exist, who acted as a bridge between extra-
cellular occurrences and intracellular changes. We then fo-
cused on astrocytes to investigate the link between Aβ and
tau pathology from the perspective of the interrelationship
between neurons and astrocytes. Garwood et al. suggested
that it was possible that astrocyte-derived cytokines bound
to neuronal plasma membrane receptors, inducing specific
signaling pathways that resulted in the activation of tau
kinases implicated in aberrant tau phosphorylation [19].
We propose a novel pathway in which released Aβ induces
IGFBP-3 in astrocytes, which leads to tau phosphorylation
via GSK-3β (Fig. 8).
Reactive astrocytes are frequently found around amyloid
plaques in both AD brains and animal models [27, 28],
suggesting that Aβ may activate astrocytes. Aβ was re-
ported to cause the deregulation of cellular Ca2+ signaling
[29–31]. One of the Ca2+-dependent protein phosphatases
is CaN [32, 33]. CaN is activated by Ca2+ and calmodulin
binding. Liu et al. reported that CaN A underwent prote-
olysis by activated calpain I at lysine 501 to generate a 57-
kDa truncated form in the AD brain, and this cleavage
markedly activated the Ca2+/calmodulin-dependent phos-
phatase activity of CaN [37]. In this study, we also
confirmed that activated forms of CaN were increased in
AD brains in comparison to non-AD controls (Fig. 5).
Moreover, we determined that the upregulated CaN was
localized in astrocytes from AD patients, especially in
proximity to Aβ plaques; in contrast, little CaN co-
localized with astrocytes in control brains (Fig. 6). CaN
strongly activates transcription factors involved in cyto-
kine production, phenotype switching, and many other
processes [44, 45]. In the case of the overexpression of ac-
tive CaN, most astrocyte-related growth factors/cytokines
A
B
Fig. 5 Calcineurin activation in human brains. Brain homogenates of the temporal cortex from AD patients (AD, n = 5) and age-matched non-AD
controls (control, n = 5) were analyzed via western blot using anti-calcineurin and anti-β-actin antibodies (a). The 45 kDa bands represent the
activated form of calcineurin, and the 60 kDa bands represent full-length calcineurin. The band densities of calcineurin were quantified using
Image J. The ratio of the activated form to full-length calcineurin (activated form/full length) was calculated and analyzed using Mann-Whitney’s
U test. The activated form/full length ratio was significantly increased in the brains of AD patients (b, 164.1 ± 11.4 %, p < 0.05). The data represent
the mean ± SE. * indicates statistically significant differences (*p < 0.05)
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or their receptors are upregulated, suggesting that CaN
acts upstream of these factors [34]. It is emphasized that
neuroinflammation significantly contributes to AD patho-
genesis and cytokines and chemical mediators play a key
role in inflammatory processes in AD [46–48]. This time,
we identified the chemical mediators released by murine
astrocytes after Aβ treatment. Among them, we focused
on IGFBP-3 and examined whether or not IGFBP-3 was
the downstream of CaN. By inhibiting CaN, the levels of
both IGFBP-3 mRNA and protein were significantly
downregulated (Fig. 4), indicating that astrocytes
expressed IGFBP-3 via the CaN cascade.
The IGFs are growth-promoting peptides that share sig-
nificant structural homology with insulin. Unlike insulin,
IGFs circulating in the plasma bind IGFBPs to form the
IGF-IGFBP complex [55]. IGFBPs have a specifically high
affinity for IGFs and are known to regulate the bioactivity
of IGFs both positively and negatively [56–60]. IGFBP-3 is
most abundant among the six different subtypes of
IGFBPs [61, 62].
IGF-I promotes neuronal survival largely through the
phosphoinositide 3-kinase (PI3K)/AKT signaling pathway
[58]. The binding of IGF-I to its receptor, IGF-IR, activates
AKT. Activated AKT phosphorylates and inhibits GSK-3β.
GSK-3β mediates the hyper-phosphorylation of tau [63]
and impairs learning and memory by preventing the
induction of long-term potentiation [64]. The IGF system
is neuroprotective against Aβ-induced cell death [65] and
beneficial for cognition [66].
Conversely, attenuation of IGF signaling is presumed to
lead to neurotoxic. Given insulin resistance is defined as a
condition in which insulin signals fail to work, despite the
presence of a sufficient amount of insulin.[67], reduced
cellular responsiveness to IGF is put into IGF resistance.
Insulin resistance has been reported to be implicated in the
pathogenesis of AD [68–72]. Similarly, many reports
suggest that IGF-Ι resistance [73, 74] plays a crucial role in
the pathogenesis of AD. Although serum IGF-Ι levels are
increased during the early stages of disease [75], major
impairments in IGF gene expression and receptor signaling
A B C
D
G H I J
K
E F
Fig. 6 Calcineurin in astrocytes from human brains. Confocal merged images of the double-fluorescence immunohistochemical study of GFAP (green)
and calcineurin (CaN) (red). Representative images from a control brain (a-c) and an AD brain (d-f) are shown. B, C, E and F are higher magnification
images. Little CaN was found in astrocytes from control brains (a-c), whereas increased expression of CaN was observed in astrocytes from AD patients
(d-f) Triple-fluorescence labeling of β-amyloid with FSB (blue) (g), GFAP (green) (h) and CaN (red) (i) in AD brains revealed the upregulation of CaN in
astrocytes (I and J, white arrow) in the proximity of Aβ plaques (g and j, white circle). We took nine independent randomly chosen low magnification
images from each of four patients and counted the number of astrocytes that expressed CaN out of the total number of astrocytes. More astrocytes
express CaN in AD brains than in control brains (n = 5, 210.3 ± 2.2 %, p < 0.05). The data represent the mean ± SE. * indicates statistically significant
differences (*p < 0.05). These human brain samples were from the temporal cortex
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have been observed in the brains of AD patients [73,
76–78]. IGFBP-3 could participate in IGF- I resistance
by disrupting IGF-I-induced survival [65]. In this study,
an experiment using primary murine neurons showed
that IGFBP-3 precluded the IGF-induced Ser9 phos-
phorylation of GSK-3β (Fig. 7a and b) and that IGFBP-
3 counteracted the effect of IGF-Ι to promote tau
phosphorylation (Fig. 7c and d). Moreover, our study
demonstrated that IGF-Ι rescued murine primary
neurons from Aβ-induced cell death and that IGFBP-3
inhibited the pro-survival effect of IGF-Ι (Fig. 7g).
Thus, IGFBP-3 clearly contributed to neuronal damage
under our experimental conditions.
In addition, IGFBP-3 has been shown to induce apop-
tosis and inhibit cell growth independent of IGFs [79–81].
The apoptotic effects of IGFBP-3 have been reported in
cells lacking the IGF-I receptor [80], and a function of







Fig. 7 The effects of IGFBP-3 on the phosphorylation of GSK-3β and tau, and on cell death. Primary murine neurons were treated with Aβ1–42 (1 μM),
IGF-1 (100 ng/ml) and IGFBP-3 (100 ng/ml), as designated in the figure, for 48 h. Western blotting analysis of primary murine neurons revealed that Aβ
reduced the inhibitory phosphorylation of GSK-3β at Ser9 (n = 6, p < 0.01), but IGF-1 restored the level of Ser9 phosphorylation (a and b, p < 0.001).
The ratio of phosphorylated GSK3β to the total, normalized by β actin, is shown, converting the value of pre-treatment into 1(b). IGFBP-3 precluded
IGF-induced Ser9 phosphorylation (p < 0.01). On the other hand, Aβ induced tau phosphorylation of murine primary neurons after 48 h of treatment
(c and d, n = 6, p < 0.001). The ratio of phosphorylated tau to the total, normalized by β actin, is shown, converting the value of pre-treatment into
1(d). Although IGF-1 suppressed tau phosphorylation, IGFBP-3 counteracted the effect of IGF-1 (c and d, p < 0.05).To examine phosphorylation of tau in
murine primary neuron when treated by astrocyte-cultured media, two dishes were prepared, one on which primary astrocytes spread and the other
on which no cell spread. The culture medium was each collected after a 48-h treatment with 1 μM Aβ. Primary neurons were treated with the media
which added 100 ng/ml IGF-Ι for 48 h and subjected the cell lysate to western blot. Astrocyte-cultured media induced tau phosphorylation in primary
murine neurons in comparison to the control.as detected by both the AT8 antibody and AT180 antibody (e). The ratio to the control of AT8 (n = 3
157.34 ± 3.44 %, p < 0.001) and AT180 (n = 3 133.63 ± 1.96 %, p < 0.05), respectively, are shown, which value was corrected by total tau and βactin (f).
Primary murine neurons were treated with Aβ1–42, IGF-1 and IGFBP-3 for 72 h and subsequently were subjected to an MTT assay to examine cell death
(n = 16). IGF-1 attenuated the neuronal cell death induced by Aβ (155.1 ± 5.7 %, p < 0.05), but IGFBP-3 inhibited the pro-survival effect of IGF-1
(g, p < 0.05). The data represented by the mean ± SE. * indicates statistically significant differences (*p < 0.05, **p < 0.01, ***p < 0.001)
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indicating the existence of an IGF-independent mode of
IGFBP-3 action.
Rensink et al. reported that IGFBP-3 levels were ele-
vated in AD brains and that the incubation of cultured
human brain pericytes with Aβ1-40 increased IGFBP-3
mRNA levels. High levels of IGFBP-3 have also been
demonstrated to exist within hyperphosphorylated tau-
positive neurons and around some Aβ plaques in AD
patients [84]. In our study, increased expression of
IGFBP-3 was observed in AD brains in comparison to
non-AD controls (Fig. 3). Moreover, IGFBP-3 frequently
existed within Aβ plaques (Fig. 3), indicating that
IGFBP-3 is involved in AD pathogenesis. Accordingly,
serum IGFBP-3 concentrations were increased in AD
and mild cognitive impairment (MCI) patients in com-
parison to controls [49].
Conclusions
In summary, our study suggested that CaN was acti-
vated by Aβ in astrocytes, leading to the release of
IGFBP-3. We further demonstrated that the IGFBP-3
produced by astrocytes in turn suppresses IGF-Ι in-
duced GSK-3β phosphorylation in neurons. This
could lead tau phosphorylation in neurons. As dis-
cussed above, the molecular process that directly con-
nects Aβ and NFT has not yet been revealed. Our
study provides novel insights into the role of astro-
cytes in the induction of tau phosphorylation and
suggests that IGFBP-3 could be an important link




The following antibodies and reagents were used in the
study:
anti-β-actin antibody, control normal mouse IgG,FK506,
IGF-Ι(Sigma Aldrich, St. Louis, Missouri, USA), mouse
monoclonal antibody to PHF-tau (AT8 and AT180)
(Thermo Scientific, Waltham, Massachusetts, USA), and
Alexa Fluor 546 goat anti-rabbit IgG conjugate and Alexa
Fluor 488 goat anti-mouse IgG conjugate (life technolo-
gies, Carlsbad, California, USA). Synthetic Aβ1–42 peptides
and Aβ42-1 peptides (Peptide Institute Inc., Osaka, Japan)
mouse monoclonal IGFBP-3 for WB(R and D systems,
Minneapolis, Minnesota, USA),rabbit polyclonal IGFBP-3
for immunostainig(Santa Cruz biotechnology, Dallas,
Texas, USA), rabbit polyclonal CaN A (Enzo life science,
Farmingdale, NY, USA),rabbit polyclonal AKT, p-AKT, p-
GSK-3β(Ser 9) and mouse monoclonal GSK-3β(cell
signaling technology, Danvers, Massachusetts, USA), FSB
solution(Wako, Osaka, Japan), mouse monoclonal GFA-
P(Abcam, Cambridge, UK), IGFBP-3 peptide(Novus bio-
logicals, Littleton, Colorado, USA).
Antibody array
An antibody array (RayBio® Biotin Label-based Mouse
Antibody Array I, RayBiotech, Inc., Norcross, Georgia,
USA) was used according to the manufacturer’s instruc-
tions. Briefly, primary mouse astrocytes were cultured
with 0.2 % fetal bovine serum (FBS) and 1 μM Aβ1–42 or
synthetic peptide Aβ42-1 (inverted sequence of Aβ) for
48 h. The culture medium was collected and dialyzed
with phosphate buffered saline (PBS, pH 8.0). The mem-
branes were incubated with blocking buffer for 1 h and
then with biotin-labeled medium for 2 h at room
temperature. The membranes were reacted with detec-
tion buffers and exposed to X-ray films.
Human brain sample
Human brain tissues were collected from the Tokyo
Metropolitan Institute of Medical Science (Table 1). All
brain samples were dissolved in radioimmune precipita-
tion assay buffer (50 mM Tris-HCl, 150 mM NaCl, 1 %
Triton X-100, 1 % Nonidet P-40, 0.5 % deoxcholate,
0.1 % SDS, pH8.0) with protease inhibitor mixture
(Roche Diagnostics GmbH, Mannheim Germany) and
homogenized enough on ice. These samples were then
centrifuged at 14,000 × g for 20 min at 4 °C and their
supernatants were collected for using Western blot ana-
lysis. The protein concentration was determined using
the BCA assay.
Fig. 8 Hypothetical model of AD pathogenesis from the perspective
of the astrocyte-neuron interaction. The hypothetical pathway by
which Aβ affects both astrocytes and neurons, thereby activating
GSK3β and leading to tau phosphorylation. Aβ, which is released
from neurons, may induce astrocytes to release IGFBP-3 by activating
calcineurin. Aβ may also directly activate GSK-3β, resulting in tau
phosphorylation. IGF-1 can suppress GSK-3β and prevent tau
phosphorylation, whereas IGFBP-3 impedes the protective effect
of IGF-1
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All autopsies were undertaken with informed consent
and the investigation was approved by the official ethical
committees of Kyoto University and of Tokyo Metropol-
itan Institute of Medical Science.
Immunostaining
Human floating sections from the temporal cortex
were obtained from the Tokyo Metropolitan Institute
of Medical Science. After blocking in PBS containing
0.1 % Tween 20 (PBS-t) with 1 % H2O2, these sec-
tions were incubated with the primary antibodies in
PBS-t for 3 days at 4 °C. These sections were washed
three times (10 min each wash) with PBS and incu-
bated with the secondary antibodies for 3 h at room
temperature. Finally, the sections were washed three
more times (10 min each wash). For experiments
using FSB (Wako) to label amyloid plaques, the sec-
tions were then incubated with FSB for 30 min. The
sections were then coverslipped with the mounting
medium. To label astrocytes, mouse monoclonal anti-
GFAP (1:500; Sigma-Aldrich) was used as the primary
antibody and Alexa Fluor 488-conjugated goat anti-
mouse (1:1000; Life Technologies) was used as the
secondary antibody. To label IGFBP-3, rabbit poly-
clonal anti-IGFBP-3 (1:500; Santa Cruz) was used as
the primary antibody and Alexa Fluor 546-conjugated
mouse anti-rabbit (1:1000; Life Technologies) was
used as the secondary antibody. To label CaN, goat
monoclonal anti-CaN (1:500; Enzo) was used as the
primary antibody and Alexa Fluor 546-conjugated
goat anti-rabbit (1:1000; Life Technologies) was used
as the secondary antibody. These sections were ob-
served using a laser confocal scanning microscope
(FV10i-LIV, Olympus, Tokyo, Japan).
To count the number of GFAP-positive cells that
expressed CaN, we chose the following method. We
tuned in to the wavelength of GFAP and took several
pictures wherein some GFAP-positive cells were ob-
served in a low-power field. We randomly selected and
marked twenty cells per sample. Next, we tuned in to
the wavelength of CaN and measured the ratio of the
co-localization of CaN with the marked cells.
Cell culture and cell treatment with reagent
Primary murine astrocytes were obtained from postnatal
day 1 (P1) mice. Briefly, cerebral cortices were collected,
rinsed 7 times with ice-cold solution minimal essential
medium (SMEM) (Sigma Aldrich), dissociated by gentle
trituration with fire-polished glass Pasteur pipettes, and
centrifuged (1,000 rpm, 4 °C, 10 min). The cell pellet
was resuspended in Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma Aldrich) containing 10 % fetal bovine
serum (FBS) (Invitrogen, USA) and 1 % penicillin/
streptomycin (PS) (Nakalai tesque, Kyoto, Japan) and fil-
tered through a 100 μm nylon mesh. The dissociated
cells were seeded into 75-cm2 tissue culture flasks and
incubated in 5 % CO2 at 37 °C. The cells were fed every
3-4 days and were grown for 20-24 days until the culture
became confluent. Glial cultures were shaken at
400 rpm (37 °C, 10 min). After the recovering the cul-
ture (37 °C, 2 h), the glial cultures were shaken again at
a lower speed (220 rpm, 37 °C, 15 h) to dislodge micro-
glia and oligodendrocytes. After washing 3 times with
SMEM, the astrocyte cultures were detached with
SMEM containing 0.25 μg/ml of trypsin (5 ml per flask,
37 °C, 15 min). An equal volume of culture medium was
added to stop the trypsin digestion. The suspension was
centrifuged (1,000 rpm, 24 °C, 10 min) and resus-
pended in DMEM with 10 % FBS and 1 % PS
(DMEM/10 % FBS/1 % PS). The seeding density was
2.5 × 104 cells/cm2. The cells present in the culture
were shown to be astrocytes, with a purity of 97 ±
2 %, after characterization via immunostaining using a
specific anti-GFAP primary antibody.
Table 1 Characteristics of human brain samples
case age sex clinical diagnosis pathological findings
non-AD Case1 75 Male schyzophrenia Plaque(-),NFT stage II
Case2 81 Female iliopsoas abscess Plaque(-),NFT stage II
Case3 62 Male schyzophrenia Plaque(-),NFT stage II
Case4 77 Male liver cirrhosis Plaque(-),NFT stageI- II
Case5 80 Female abdominal aortic aneurysm Plaque(-),NFT stage II
AD Case1 75 Alzheimer disease NFT stageVI,C
Case2 68 Alzheimer disease NFT stageVI,C
Case3 75 Alzheimer disease NFT stageVI,C
Case4 77 Alzheimer disease NFT stageVI,C
Case5 86 Alzheimer disease NFT stageVI,C
Clinical and histopathological information pertaining to the brain samples used in this study. We analyzed five brains from patients with neuropathology-
confirmed AD and five brains from control subjects. No significant differences in age were observed between the AD and control cases. NFT neurofibrillary tangle
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H4 cells (derived from human astrocytoma) were
maintained in DMEM/10 % FBS/1 % PS at 37 °C in a
5 % CO2 incubator. mRNA was extracted from H4 cells
and subjected to quantitative RT-PCR. Similarly, after
treatment with 1 μM Aβ1–42, control peptide and 1 μM
Aβ1–42 with 1 μM FK506 (Sigma Aldrich) for 48 h, the
cell lysates and media were subjected to western blot
analysis and ELISA, respectively.
Primary murine neuron cultures were obtained from the
cerebral cortices of fetal mice (14-16 days of gestation)
and cultured in neurobasal medium (Sigma Aldrich) sup-
plemented with B-27 (Invitrogen) and glutamine (Sigma
Aldrich). After incubation for 10 days, the cells were
treated with Aβ1–42 (1 μM), Aβ1–42 (1 μM), IGF-Ι (100 ng/
ml) and IGFBP-3 (100 ng/ml) for 48 h. The cells were
washed twice in phosphate-buffered saline (PBS) and
scraped off of the plates. The cell pellets were lysed in ice-
cold TNE buffer (10 mM Tris-HCl, 150 mM NaCl, 1 %
Nonidet P-40 (Roche Applied Science, Penzberg, Upper
Bavaria, Germany), 1 mM EDTA, pH 7.8) containing a
protease inhibitor mixture and briefly subjected to sonic-
ation. The samples were centrifuged at 14,000 × g for
5 min at 4 °C, and the supernatants were collected to
obtain protein samples. The protein concentration was
determined using the Bradford assay [85].
In the experiment to examine the effect of astrocyte-
cultured media, we prepared two dishes, one on which
primary astrocytes spread and the other on which no cell
spread. The culture medium was each collected after a
48-h treatment with 1 μM Aβ. The media were centri-
fuged at 14,000 × g for 5 min at 4 °C, and the superna-
tants were collected for treatment. We treated primary
neurons with the media which added 100 ng/ml IGF-Ι
for 48 h and subjected the cell lysate to western blot.
Western blotting
Protein samples were diluted with sample buffer(125 mM
Tris-HCl, 4 % SDS, 2 % 2-mercaptoethanol, 20 % gly-
cerol, 0.01 % bromophenol blue, pH6.8) and denatured
at 95 °C for 3 min. Equal amounts of samples were sepa-
rated by sodium dodecyl sulfate (SDS)-polyacrylamide
gradient gels (5–20 %; Atto, Tokyo, Japan) in running
buffer (25 mM Tris, 192 mM glycine and 0.1 % SDS),
followed by Western blot, using polyvinylidene difluor-
ide microporous membrane, blocking this membrane in
blocking One (Nacalai tesque), and incubating with the
primary antibodies in PBS containing 4 % BSA (Nacalai
tesque) overnight at 4 °C. The membranes were then
washed with 20 mM TBS containing 0.1 % Tween 20
(TBS-t) and incubated with horseradish peroxidase-
conjugated anti-mouse or anti-rabbit IgG (GE Health-
care, Little Chalfont, UK) in TBS-t for 1 h at room
temperature. The specific reaction was visualized using
the ECL method (GE Healthcare).
Real-time polymerase chain reaction (PCR) assay
Total ribonucleic acid (RNA) was extracted using ISO-
GEN (NIPPON GENE, Tokyo, Japan) according to the
manufacturer’s protocol. cDNA was produced from each
5 μg RNA sample using a cDNA synthesis kit (GE
Healthcare).
Real-time PCR primers were designed as follows: IGFBP-
3: 5’-ACAGCCAGCGCTACAAAGTT-3’ and 3’-GGCTGC
CCATACTTATCCAC-5’, βactin: 5’-CACACTGTGCCCAT
CTAC-3’ and 3’-GATCTGAAGCTCGTCCTC-5’. For the
amplification of IGFBP-3 and β-actin, 5 μl of cDNA was
added to the SYBR green master mix (Roche), and a real-
time PCR assay was performed using a Light cycler480
(Roche).
ELISA
The levels of IGFBP-3 in culture media were measured
by human IGFBP-3 ELISA kits (R and D systems), ac-
cording to the manufacturer’s instructions.
MTT
MTT assay was performed using the MTT cell prolifera-
tion assay kit (Cayman chemical, Ann Arbor, Michigan,
USA) according to the manufacturer’s instructions.
Statistic analysis
The band densities of WB were quantified by Image J.
Comparisons were performed using a Student’s t test.
For comparison of multiparametric analysis, one-way
ANOVA, followed by the post hoc analysis by Fisher’s
protected least significant difference (PLSD) was used.
The significance was defined by STATVIEW software.
All values were given in means ± SE, and statistical sig-
nificance was suggested at p < 0.05.
Additional file
Additional file 1: The effects of IGFBP-3 on the phosphorylation of
tau (AT180). To confirm the effect of IGFBP-3 on phosphorylation of tau,
the same experiment was done by using another antibody, AT180. Primary
murine neurons were treated with Aβ1–42 (1 μM), IGF-1 (100 ng/ml) and
IGFBP-3 (100 ng/ml), as designated in the figure. Western blotting analysis
of primary murine neurons revealed that Aβ induced tau phosphorylation
of murine primary neurons after 48 h of treatment (A and B, n = 4, p < 0.01).
Phosphorylated tau normalized by β actin, is shown, converting the value of
Aβ-treatment into 1(B). Although IGF-1 suppressed tau phosphorylation,
IGFBP-3 counteracted the effect of IGF-1 (A and B, p < 0.01). * indicates
statistically significant differences (*p < 0.01). This result was compatible with
the one from AT8. (PDF 222 kb)
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